Dr. Pat Soon-Shiong
@DrPatrick • 155,346 subscribers
Chairman of Chan Soon-Shiong Family Foundation, Exec Chairman ImmunityBio, Chairman and Chief Executive Officer of Los Angeles Times Media Group (LATMG)
Shorts
Videos
Amazing, a former FDA associate commissioner Peter J. Pitts affirmed that the mechanism of action in the approved label confirms the science of Anktiva, by the FDA itself. Jay Bhattacharya agrees with Dr. Pitts and highlights the new path just released by Dr. Marty Makary of the “Plausible Mechanism of Action” to expedite and accelerate access to the American public. Two senior thoughtful members of the panel, a former FDA senior official and the present NIH/CDC director now affirm that the plausible mechanism of action is the path to rapid access. This is what we have been presenting to the FDA for the past 6 months to desperately allow the 13,000+ requests from Americans to access Anktiva via this pathway. A groundswell of patients desperate for this to happen is growing and I am pleased that Christopher C. Cuomo promised that this conversation will continue… as it must.
Dr. Pat Soon-Shiong825,140 views • 3 months ago
My meeting with President Donald J. Trump and HRH MBS in May 2025 resulted in such amazing results and action! In less than a year we received the world’s first approval for lung cancer for the Bioshield… and now we have established a wholly owned subsidiary in the Kingdom to support physicians and healthcare systems throughout the MENA region. Distribution readiness of Anktiva for both bladder and lung cancer patients since approval just one year ago will amaze all at the speed… congratulations to our team ImmunityBio, Inc. who worked tirelessly to make this happen and ensure rapid access of the Bioshield to patients in the Kingdom... stay tuned!
Dr. Pat Soon-Shiong655,726 views • 3 months ago
How do you defend a "no" to access for patients desperately seeking treatment, when the package insert affirms the mechanism that Anktiva activates T cells and NK cells? Peter J. Pitts provides the amazing truthful response that there is no reason. He highlights the mechanism of action in the package insert already approved. Peter also provides insight into the inconsistencies at the FDA when dealing with large pharma regarding approval with single arm trials versus biotech companies with a mission to cure cancer.
Dr. Pat Soon-Shiong539,943 views • 3 months ago
Introducing the NANT Leonardo Robot with zero human touch points to produce valuable NK cells to protect our immune system. Imagine a world where immune cells are manufactured by AI driven robots. This is where the power of AI is used for the good of all humanity, making expensive cell therapy affordable to all. Soon we will be launching a manufacturing plant filled with robots and machine vision trained AI to generate the "World Bank of NK Cells". Immunotherapy 2.0 on a global basis. Imagine a robot like Optimus loading the NANT Leonardo Robot with the raw materials needed. Elon Musk
Dr. Pat Soon-Shiong585,830 views • 4 months ago
My talk on Feb 24 at the 55th anniversary of President Nixon's war on cancer. Deconstructing the mind map for the first time in ten years. A good prelude to the discussion at the ImmunityBio, Inc. annual update on March 3 at 1:30pm ET. To listen to the update, the link is below.
Dr. Pat Soon-Shiong425,366 views • 3 months ago
We have studied papillary disease in bladder cancer since 2015. These patients with non-muscle invasive bladder cancer (NMIBC) receiving Anktiva and BCG for the first time are STILL FREE OF CANCER now 10 years and going! The power of NK and memory T cells. ImmunityBio, Inc.
Dr. Pat Soon-Shiong499,186 views • 4 months ago
Cancer is a shape shifting disease. We have figured a way to outsmart it through the power of IL-15 and natural killer cells. By 2026 we will grow trillions of natural killer cells from healthy donors and generate the 'world bank of natural killer cells' which can be administered to any patient without donor matching. That is how natural killer cells work. Special Report Bret Baier
Dr. Pat Soon-Shiong348,772 views • 3 months ago
I’m taking sections of my talks… I have given hundreds… and transferring the talks into this AI tool to better explain our decades of work. So connecting the dots again but with an AI tool! Here is our talk on the original flaw and how IL-15 was the missing link
Dr. Pat Soon-Shiong228,562 views • 3 months ago
So exciting to see the results of Anktiva in bladder cancer in women who tend to have higher-grade and more advanced tumors, resulting in a higher risk of recurrence and lower survival rates compared to men. Grateful for Deborah allowing us to tell her story of papillary disease that then recurs to CIS with BCG alone... and now in complete remission after Anktiva + BCG. Further evidence that papillary and CIS disease are clonally the same.
Dr. Pat Soon-Shiong223,053 views • 3 months ago
Wow, first I discovered the 2007 NIH workshop that ranked Il-15 the number one immunotherapy to cure cancer, now I find a 2017 lecture on IL-15 by NIH AND NCI describing its power. Building on the shoulders of immunology giants at the NIH and NCI , the late Drs William E. Paul and Thomas Waldman. This is such an important lecture for all to listen to and to comprehend the future of immunotherapy 2.0. I post the video in my tweet in which we have shortened the introduction to start with the lecture. The full video is here: The immense power and value of IL-15 was recognized almost 20 years ago. Amazingly, Dr. Waldman foresaw the need to COMBINE IL-15 (today's ANKTIVA) with a checkpoint inhibitor (today's Keytruda) in order to maximize T cell activity as well as stimulate macrophages (today’s Abraxane). This is what the Saudi FDA scientists and regulators at the SFDA recognized - the power of IL15 and Anktiva as the backbone and that is why we have the world's first approval for ANKTIVA in combination with checkpoint inhibitor in Saudi Arabia. This is such an important lecture that every regulatory authority in the world should study and understand the evolutionary science of the immune system and the importance of appropriate combinations… so important for science to drive regulatory decision-making, especially for the reviewers who may not be trained immunologists and coming to conclusions based on past archaic practices. Oncology and infectious disease is now fundamental immunology. So hopeful that regulatory reviewers around the world watch this... It is such an important educational video of what we have been building at IBRX that I will leave this pinned for a month!!! So inspired to see that we have been independently pursuing the right strategy for the past decade. The power of immunotherapy 2.0 is clearly spelt out in Dr Walkman’s talk in 2017 where he explains why T cell memory is needed to cure cancer and why orchestrated sequenced combinations are needed. Anktiva which grows and activates T and NK cells, Abraxane that induces DAMPs and activates macrophages, and checkpoint inhibitors that take the brakes off T cells is THE FUNDAMENTAL COMBINATION DESCRIBED by NCI scientists a decade ago in this lecture! Remarkably, Dr. Waldman shows that when administered as single-agents, these molecules did not achieve durable complete remissions but when placed in the correct sequence of combination therapy, magic happens. Quantum oncotherapeutics So please share this video with whomever wants to be enlightened that immunotherapy 2.0 now exists and has been studied in multiple Quantum Oncotherapeutics trials across multiple tumor types under QUILT
Dr. Pat Soon-Shiong183,339 views • 3 months ago
Here is the exciting world of AI. My presentation of the cancer mind map after a decade of work to prove the hypothesis that empowering the innate and adaptive immune system could cure cancer. So I dictated some of my talk to an AI platform and became the "source" that is mentioned in this audio... amazingly, it took my mind map and created this conversation! Take a listen, it explains beautifully how we think about attacking cancer.
Dr. Pat Soon-Shiong193,614 views • 3 months ago
Thanks Ashish Ashish M. Kamat, MD, MBBS. Your book entitled, "Bladder Cancer: A Practical Guide" says it all. Together we face patients on a day-to-day level in which we have to make decisions in the best interest of the patient with nothing else considered. I was so grateful for you to have shared with me your views on whether CIS and papillary from a clinical perspective was the same disease and also how you treat patients who have failed all BCG and have papillary disease and face losing their bladder to a life-changing operation of cystectomy. I was blown away at this year's #AUA2026 when a researcher presented a slide showing that the morbidity and mortality of a cystectomy exceeds even that of a Whipple in which the pancreas, gallbladder portion of the stomach and spleen are all removed. That blew my mind especially since there is an option to save the bladder. I am posting the segment of our long conversation relating to your views of whether CIS and high grade papillary are treated clinically as the same disease. I was glad to hear the next day at the FDA workshop that your fellow expert colleagues completely agreed with this sentiment that you expressed in our conversation.
Dr. Pat Soon-Shiong41,421 views • 25 days ago
Next onto my conversation with Dr. Ashish Kamat Ashish M. Kamat, MD, MBBS and one of the country's leading bladder cancer experts to hear his clinical decision making process as to how he treats patients with BCG unresponsive high-grade papillary disease when no CIS disease is found. (I said the word 'found' since sometimes once high-grade papillary disease is identified, physicians don't bother to look for CIS since their decision making process for treatment is the same if high-grade papillary alone exists. Worse, only 6% of urologists have the blue-light cystoscopy scope that helps them find CIS disease). Dr. Kamat who participated in the initial guidelines discussion with regard to BCG unresponsive in 2016, gave me an insightful answer as to how he treats patients clinically with high-grade papillary alone. Please listen to his insightful answer, the editor of the seminal textbook entitled, "Bladder Cancer: A Practical Guide". He treats patients with high-grade papillary disease alone no differently than in patients with high-grade papillary and CIS disease. This was not surprising for me to hear since he and many others believe that CIS and papillary are the same disease! The next day I attended the FDA workshop in which his fellow colleagues concurred that CIS and papillary was the same disease and also said that they approached patients with BCG unresponsive high-grade papillary disease in the same way as he shared with me in this interview, taken the day before the FDA workshop. His fellow colleagues and experts at the workshop said that they "struggled" and were compelled to make decisions with no option but to prescribe "off-label" therapies for patients who they see (with papillary disease alone) by writing a prescription for already FDA approved therapies for papillary and CIS disease. So the consensus at this panel completely matched the panel of experts from comprehensive cancer centers across the nation who made up the NCCN and provided category 2A status for Anktiva + BCG for the treatment of BCG unresponsive papillary disease alone. Cancer is a war against time Disclaimer: Anktiva + BCG for the treatment of BCG unresponsive papillary disease is not approved and is awaiting review by the FDA as a supplemental BLA. For more details of ANKTIVA + BCG, please refer to our package insert and important safety information. ANKTIVA is approved by the FDA in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. Important Safety Information U.S. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Indication and Important Safety Information and Prescribing Information for ANKTIVA® at
Dr. Pat Soon-Shiong20,475 views • 25 days ago
In 2020 I gave this talk on "Quantum Oncotherapeutics" for oncologists to grasp a change is coming. Complex evolution of the immune system and basis for #bioshield for cancer. Hundreds of inquiries since my chat with Tucker Carlson - we are trying hard to respond to all. #cancer
Dr. Pat Soon-Shiong223,364 views • 1 year ago
Honored to be at State Dinner with Donald J. Trump & Emir Tamim bin Hamad Al Thani. Palace is breathtaking & Royal family such gracious hosts. Qatar USA oldest friend. Foundation for peace in Middle East is now in place. #POTUS focused in on cancer & changing lives #Bioshield
Dr. Pat Soon-Shiong158,283 views • 1 year ago
The amazing dedicated team at CSSIFM treating our cancer patients with NK cells in clinical trials. So many requests from patients who have failed all standards of care and they are working so hard to file for FDA authorization as many single patient INDs as we can. Happy Easter and stay safe
Dr. Pat Soon-Shiong32,595 views • 2 months ago